NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

表紙
市場調查報告書

黑色素瘤 (惡性黑色素瘤) - 至2029年的流行病學預測

Melanoma - Epidemiology Forecast to 2029

出版商 GlobalData 商品編碼 1000682
出版日期 內容資訊 英文 41 Pages
訂單完成後即時交付
價格
黑色素瘤 (惡性黑色素瘤) - 至2029年的流行病學預測 Melanoma - Epidemiology Forecast to 2029
出版日期: 2021年04月15日內容資訊: 英文 41 Pages
簡介

主要8個國家 (美國、法國、德國、義大利、西班牙、英國、澳洲、加拿大) 的黑色素瘤 (惡性黑色素瘤) 和確診的發病病例,從2019年的190,771病例,到2029年增加到222,458病例,預計以AGR1.66%成長。

的黑色素瘤 (惡性黑色素瘤) 調查分析,危險因素,合併症,全球趨勢,10年本報告提供主要8個國家的流行病學預測相關的系統性資訊。

目錄

第1章 目錄

第2章 黑色素瘤 (惡性黑色素瘤) :摘要整理

第3章 流行病學

  • 疾病的背景
  • 危險因素和合併症
  • 世界趨勢與歷史的趨勢
  • 預測手法
  • 黑色素瘤 (惡性黑色素瘤)的流行病學預測
    • 黑色素瘤 (惡性黑色素瘤) 和確診的發病病例
    • 黑色素瘤 (惡性黑色素瘤) 和確診的發病病例,性別
    • 黑色素瘤 (惡性黑色素瘤) 和確診的發病病例,各年齡
    • 黑色素瘤 (惡性黑色素瘤) 和確診的發病病例,各病期分類
    • 黑色素瘤 (惡性黑色素瘤) 確診的發病病例,各變異
    • 黑色素瘤 (惡性黑色素瘤) 和確診的有病例 (5年)
  • 討論
  • 流行病學預測的考察

第4章 附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GDHCER269-21

Melanoma is a malignant neoplasm of melanocytes, the pigment cells in the skin located on the epidermis, the most superficial layer of the skin (World Health Organization, 2017). Melanocytes are embryological derivatives of neural crest tissue, and as such, any region of the body that is a derivative of the neural crest and contains melanocytes, namely areas of skin, meninges, mucous membranes, esophagus, and eyes, can develop melanoma (Komarnicky-Kocher and Alite, 2013). Accordingly, non-cutaneous melanomas typically occur in the eye and mucosa and account for only 4-5% of primary melanomas. This report focuses on melanoma of the skin (International Statistical Classification of Diseases and Related Health Problems, Tenth Revision [ICD-10] Code: C43) (Centers for Disease Control and Prevention, 2020; Mayo Clinic, 2020). Melanoma typically presents as a mole (nevus) on the skin, and is characterized by the growth's asymmetry, irregular border, color variation, diameter greater than six millimeters, and evolution in appearance over a few weeks or months; these five diagnostic characteristics are known collectively by the acronym ABCDE (Gadeliya Goodson and Grossman, 2009; Goodman and Snyder, 2012).

In the 8MM, GlobalData epidemiologists forecast the diagnosed incident cases of melanoma to increase from 190,771 cases in 2019 to 222,458 cases in 2029, at an Annual Growth Rate (AGR) of 1.66%. The US will have the highest number of melanoma cases throughout the forecast period. The five-year diagnosed prevalent cases of melanoma in the 8MM are also expected to increase from 794,304 cases in 2019 to 947,373 cases in 2029 at an AGR of 1.93%.

Scope

  • The Melanoma Epidemiology Report provides an overview of the risk factors and the global and historical trends for melanoma in the eight major markets (8MM: US, France, Germany, Italy, Spain, UK, Australia, and Canada).
  • The report includes a 10-year epidemiological forecast for the diagnosed incident cases of melanoma segmented by age (beginning at 18 years and ending at 85 years and older), sex, cancer stage at diagnosis (American Joint Commission on Cancer [AJCC] Stages I, II, III, and IV), and mutations (BRAF, BRAF V600E, BRAF V600K, BRAF Non-V600, NF1, BRAF/NF1, NRAS Q61, C-KIT, PD-L1 expression, tumor mutational burden [TMB], NTRK - mutations in tropomyocin receptor kinase [TRK]).
  • The melanoma epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
  • The Epidemiology Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 8MM.

Reasons to Buy

The Melanoma Epidemiology series will allow you to -

  • Develop business strategies by understanding the trends shaping and driving the global melanoma market.
  • Quantify patient populations in the global melanoma market to improve product design, pricing, and launch plans.
  • Organize sales and marketing efforts by identifying the age groups that present the best opportunities for melanoma therapeutics in each of the markets covered.
  • Understand magnitude of melanoma by stage at diagnosis and mutations.

Table of Contents

1 Table of Contents

  • 1.1 List of Tables
  • 1.2 List of Figures

2 Melanoma: Executive Summary

  • 2.1 Catalyst
  • 2.2 Related Reports
  • 2.3 Upcoming Reports

3 Epidemiology

  • 3.1 Disease Background
  • 3.2 Risk Factors and Comorbidities
  • 3.3 Global and Historical Trends
  • 3.4 Forecast Methodology
    • 3.4.1 Sources
    • 3.4.2 Forecast Assumptions and Methods
    • 3.4.3 Diagnosed Incident Cases of Melanoma
    • 3.4.4 Diagnosed Incident Cases of Melanoma by Stage at Diagnosis
    • 3.4.5 Mutations Among Diagnosed Incident Cases of Melanoma
    • 3.4.6 Five-Year Diagnosed Prevalent Cases of Melanoma
  • 3.5 Epidemiological Forecast for Melanoma, 2019-2029
    • 3.5.1 Diagnosed Incident Cases of Melanoma
    • 3.5.2 Sex-Specific Diagnosed Incident Cases of Melanoma
    • 3.5.3 Age-Specific Diagnosed Incident Cases of Melanoma
    • 3.5.4 Diagnosed Incident Cases of Melanoma by Stage at Diagnosis
    • 3.5.5 Diagnosed Incident Cases of Melanoma by Mutations
    • 3.5.6 Five-Year Diagnosed Prevalent Cases of Melanoma
  • 3.6 Discussion
  • 3.7 Epidemiological Forecast Insight
    • 3.7.1 COVID-19 Impact
    • 3.7.2 Limitations of the Analysis
    • 3.7.3 Strengths of the Analysis

4 Appendix

  • 4.1 Bibliography
  • 4.2 About the Authors
    • 4.2.1 Epidemiologist
    • 4.2.2 Reviewers
    • 4.2.3 Global Director of Therapy Analysis and Epidemiology
    • 4.2.4 Global Head and EVP of Healthcare Operations and Strategy
  • 4.3 About GlobalData
  • 4.4 Contact Us
  • 4.5 Disclaimer

List of Tables

List of Tables

  • Table 1: Summary of Newly Added Data Types and Countries
  • Table 2: Summary of Updated Data Types
  • Table 3: Risk Factors and Comorbidities for Melanoma
  • Table 4: 8MM, Diagnosed Incident Cases of Melanoma by Mutations, Ages ≥18 Years, Both Sexes, N, 2019

List of Figures

List of Figures

  • Figure 1: 8MM, Diagnosed Incident Cases of Melanoma, Both Sexes, Ages ≥18 Years, 2019 and 2029
  • Figure 2: 8MM, Five-Year Diagnosed Prevalent Cases of Melanoma, Both Sexes, Ages ≥18 Years, 2019 and 2029
  • Figure 3: 8MM, Diagnosed Incidence of Melanoma, Men, Ages ≥18 Years, 2009-2029
  • Figure 4: 8MM, Diagnosed Incidence of Melanoma, Women, Ages ≥18 Years, 2009-2029
  • Figure 5: 8MM, Sources Used and Not Used to Forecast the Diagnosed Incident Cases of Melanoma
  • Figure 6: 8MM, Sources Used to Forecast the Diagnosed Incident Cases of Melanoma by Stage at Diagnosis
  • Figure 7: 8MM, Sources Used to Forecast the Diagnosed Incident Cases of Melanoma by Mutations
  • Figure 8: 8MM, Sources Used to Forecast the Five-Year Diagnosed Prevalent Cases of Melanoma
  • Figure 9: 8MM, Diagnosed Incident Cases of Melanoma, Both Sexes, Ages ≥18 Years, N, 2019
  • Figure 10: 8MM, Diagnosed Incident Cases of Melanoma, by Sex, Ages ≥18 Years, N, 2019
  • Figure 11: 8MM, Diagnosed Incident Cases of Melanoma by Age, Both Sexes, N, 2019
  • Figure 12: 8MM, Diagnosed Incident Cases of Melanoma by Stage at Diagnosis, Both Sexes, Ages ≥18 Years, N, 2019
  • Figure 13: 8MM, Five-Year Diagnosed Prevalent Cases of Melanoma, Ages ≥18 Years, Both Sexes, N, 2019